IceCure Medical (ICCM) Stock Forecast, Price Target & Predictions
ICCM Stock Forecast
IceCure Medical stock forecast is as follows: an average price target of $2.50 (represents a 123.21% upside from ICCM’s last price of $1.12) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ICCM Price Target
The average price target for IceCure Medical (ICCM) is $2.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $2.50 to $2.50. This represents a potential 123.21% upside from ICCM's last price of $1.12.
ICCM Analyst Ratings
According to 2 Wall Street analysts, IceCure Medical's rating consensus is 'Buy'. The analyst rating breakdown for ICCM stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
IceCure Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 29, 2024 | Yi Chen | H.C. Wainwright | $2.50 | $0.82 | 205.62% | 123.21% |
| May 19, 2022 | Ben Haynor | Industrial Alliance Securities | $5.75 | $1.88 | 205.85% | 413.39% |
The latest IceCure Medical stock forecast, released on Nov 29, 2024 by Yi Chen from H.C. Wainwright, set a price target of $2.50, which represents a 205.62% increase from the stock price at the time of the forecast ($0.82), and a 123.21% increase from ICCM last price ($1.12).
IceCure Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $2.50 | $2.50 | $2.50 |
| Last Closing Price | $1.12 | $1.12 | $1.12 |
| Upside/Downside | 123.21% | 123.21% | 123.21% |
In the current month, the average price target of IceCure Medical stock is $2.50, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 123.21% increase as opposed to IceCure Medical's last price of $1.12. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 19, 2022 | Alliance Global Partners | Buy | Buy | Hold |
IceCure Medical's last stock rating was published by H.C. Wainwright on Nov 29, 2024. The company gave ICCM a "Buy" rating, the same as its previous rate.
IceCure Medical Financial Forecast
IceCure Medical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $710.00K |
| Avg Forecast | $2.04M | $1.44M | $1.26M | $952.50K | $1.07M | $708.50K | $925.50K | $1.02M | $1.17M | $1.02M | $934.33K | $950.00K |
| High Forecast | $2.13M | $1.50M | $1.31M | $993.22K | $1.11M | $738.79K | $965.06K | $1.06M | $1.22M | $1.07M | $974.27K | $990.61K |
| Low Forecast | $1.95M | $1.38M | $1.20M | $911.78K | $1.02M | $678.21K | $885.93K | $973.52K | $1.12M | $977.99K | $894.39K | $909.39K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.75% |
IceCure Medical's average Quarter revenue forecast for Jun 23 based on 1 analysts is $934.33K, with a low forecast of $894.39K, and a high forecast of $974.27K. ICCM's average Quarter revenue forecast represents a 31.60% increase compared to the company's last Quarter revenue of $710.00K (Mar 23).
IceCure Medical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-3.88M |
| Avg Forecast | $-2.04M | $-1.44M | $-1.26M | $-952.24K | $-1.07M | $-708.31K | $-925.25K | $-1.02M | $-1.17M | $-1.02M | $-934.08K | $-949.74K |
| High Forecast | $-1.95M | $-1.38M | $-1.20M | $-911.53K | $-1.02M | $-678.03K | $-885.70K | $-973.26K | $-1.12M | $-977.73K | $-894.15K | $-909.14K |
| Low Forecast | $-2.13M | $-1.50M | $-1.31M | $-992.95K | $-1.11M | $-738.59K | $-964.80K | $-1.06M | $-1.22M | $-1.07M | $-974.01K | $-990.34K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 4.08% |
undefined analysts predict ICCM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than IceCure Medical's previous annual EBITDA (undefined) of $NaN.
IceCure Medical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-3.58M |
| Avg Forecast | $-2.94M | $-3.18M | $-3.18M | $-3.67M | $-3.67M | $-3.67M | $-3.43M | $-3.75M | $-3.43M | $-4.41M | $-4.24M | $-4.57M |
| High Forecast | $-2.77M | $-3.01M | $-3.01M | $-3.47M | $-3.47M | $-3.47M | $-3.24M | $-3.55M | $-3.24M | $-4.16M | $-4.01M | $-4.32M |
| Low Forecast | $-3.10M | $-3.36M | $-3.36M | $-3.88M | $-3.88M | $-3.88M | $-3.62M | $-3.96M | $-3.62M | $-4.65M | $-4.48M | $-4.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.78% |
IceCure Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ICCM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
IceCure Medical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $2.17M |
| Avg Forecast | $3.74M | $2.65M | $2.31M | $1.75M | $1.96M | $1.30M | $1.70M | $1.87M | $2.14M | $1.87M | $1.71M | $1.74M |
| High Forecast | $3.90M | $2.76M | $2.41M | $1.82M | $2.04M | $1.36M | $1.77M | $1.95M | $2.23M | $1.95M | $1.79M | $1.82M |
| Low Forecast | $3.58M | $2.53M | $2.21M | $1.67M | $1.88M | $1.24M | $1.63M | $1.79M | $2.05M | $1.79M | $1.64M | $1.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.24% |
IceCure Medical's average Quarter SG&A projection for Jun 23 is $1.71M, based on 1 Wall Street analysts, with a range of $1.64M to $1.79M. The forecast indicates a -20.85% fall compared to ICCM last annual SG&A of $2.17M (Mar 23).
IceCure Medical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.08 |
| Avg Forecast | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.08 | $-0.07 | $-0.09 | $-0.09 | $-0.09 |
| High Forecast | $-0.06 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.08 | $-0.08 | $-0.09 |
| Low Forecast | $-0.06 | $-0.07 | $-0.07 | $-0.08 | $-0.08 | $-0.08 | $-0.07 | $-0.08 | $-0.07 | $-0.10 | $-0.09 | $-0.10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.84% |
According to undefined Wall Street analysts, IceCure Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ICCM previous annual EPS of $NaN (undefined).
IceCure Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CTSO | Cytosorbents | $0.81 | $9.00 | 1011.11% | |
| TELA | TELA Bio | $2.76 | $8.00 | 189.86% | Buy |
| ICCM | IceCure Medical | $1.08 | $2.50 | 131.48% | Buy |
| SGHT | Sight Sciences | $3.62 | $7.50 | 107.18% | Hold |
| KIDS | OrthoPediatrics | $22.46 | $39.50 | 75.87% | Buy |
| BWAY | BrainsWay | $9.34 | $16.00 | 71.31% | Buy |
| CNMD | CONMED | $71.23 | $97.00 | 36.18% | Buy |
| NPCE | NeuroPace | $11.52 | $15.00 | 30.21% | Buy |
| ITGR | Integer | $136.68 | $153.50 | 12.31% | Buy |
| ESTA | Establishment Labs | $44.67 | $45.00 | 0.74% | Buy |
| SRDX | Surmodics | $39.96 | $39.50 | -1.15% | Buy |
| CLPT | ClearPoint Neuro | $16.34 | $15.00 | -8.20% | Buy |